News
-
SEC-MALS arrives at Bio21 Melbourne Protein Characterisation
31 January 2020
-
Biacore S200 arrives at Bio21
The Biacore S200 arrived at Bio21 Institute on Monday, 17 June 2019. This instrument, that is used to characterize molecular interactions, is one of a suite of instruments that has been funded by the Australian Cancer Research Foundation as part of the ACRF Facility for Innovative Cancer Drug Discovery. It is currently being installed and will be available soon.
-
Media Release: ACRF cancer research facility to harness structural biology for cancer drug discovery
28 November 2018
The Australian Cancer Research Foundation (ACRF) will provide $2 million to fund the creation of the ACRF Facility for Innovative Cancer Drug Discovery at the Bio21 Institute, University of Melbourne.
The chief investigators, Professor Michael Parker and Dr David Ascher of Bio21, Professor Rick Pearson of the Peter MacCallum Cancer Centre and Professor John Silke of the Walter and Eliza Hall Institute, represent some of Victoria’s major cancer research institutions.
-
X-ray diffractometer, a Rigaku XtalLAB Synergy S arrives at Bio21
27 November 2018
A new X-ray diffractometer, a Rigaku XtalLAB Synergy S, is the first instrument to be housed in the new Melbourne Protein Characterisation platform. This instrument is currently being installed at Bio21. Synergy S was purchased from a LIEF grant awarded to Jonathan White.
Melbourne Protein Characterization (MPC) will be comprised of four facilities, to support the protein discovery research: